FDA Brief

Warning letters Drugs

FDA warning letter to

Rohto Pharmaceutical Co., Ltd.

High riskIssued Oct 14Posted Oct 20Center for Drug Evaluation and Research (CDER)

FDA cites Rohto Vietnam eye-drop plant for falsified sterility records, poor aseptic practices, and unapproved Cooling Eye Drops.

What happened

FDA inspected Rohto-Mentholatum (Vietnam) Co., Ltd. from April 6 to 14, 2026, and found systemic falsification of environmental, personnel, and cleaning records; actual plate readings during the inspection showed microbial growth, including about 25 excursions in critical sterile areas (ISO 5). FDA also reviewed the website and Instagram in August 2026 and found seven ROHTO Cooling Eye Drops products to be unapproved new drugs and misbranded. FDA cited inadequate investigations of visible particles in two released sterile eye-drop batches and consumer complaints of leakage, burning, and foreign matter.

What FDA found

  1. The company falsified environmental, personnel, and cleaning records, including by submitting unexposed plates and documenting cleaning that was not performed.

    21 CFR 211.194(a) and 21 CFR 211.67(a)
  2. The company did not properly control aseptic (sterile) processing, with operators mishandling open sterile bottles and undocumented interventions in the ISO 5 critical area.

    21 CFR 211.113(b) and 21 CFR 211.63
  3. The company did not adequately investigate visible particles in two released sterile eye-drop batches or consumer complaints of leakage, burning, and foreign matter.

    21 CFR 211.192
  4. Seven ROHTO Cooling Eye Drops products are unapproved new drugs because they lack an FDA-approved application.

    FD&C Act section 505(a), 21 U.S.C. 355(a)
  5. The same products are misbranded under the Federal Food, Drug, and Cosmetic Act.

    FD&C Act sections 502(a) and 502(ee), 21 U.S.C. 352(a) and 352(ee)
  6. The company's drugs are adulterated because its manufacturing methods did not conform to CGMP.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)

What FDA wants

FDA tells Rohto to promptly correct the violations and provide independent assessments, corrective action and preventive action (CAPA) plans, and remediation plans for its laboratory, documentation, aseptic, cleaning, visual inspection, and quality systems. The letter does not state a specific response deadline.

Who should pay attention

  • U.S. brands and distributors selling Rohto eye drops
  • sterile ophthalmic drug manufacturers
  • quality teams that rely on environmental monitoring records

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  3. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  4. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk